Vivo Bio Tech (BOM:511509) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Vivo Bio Tech Debt-to-Equity?

Vivo Bio Tech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Vivo Bio Tech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Vivo Bio Tech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0.0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vivo Bio Tech's Debt-to-Equity or its related term are showing as below:

BOM:511509' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.4 Med: 0.79 Max: 2.15
Current: 1.15

During the past 12 years, the highest Debt-to-Equity Ratio of Vivo Bio Tech was 2.15. The lowest was 0.40. And the median was 0.79.

BOM:511509's Debt-to-Equity is ranked worse than
89.26% of 1080 companies
in the Biotechnology industry
Industry Median: 0.145 vs BOM:511509: 1.15

Vivo Bio Tech Debt-to-Equity Historical Data

The historical data trend for Vivo Bio Tech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivo Bio Tech Debt-to-Equity Chart

Vivo Bio Tech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.80

0.74

0.73

1.43

1.20

Vivo Bio Tech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	1.20	N/A	1.15	N/A

Competitive Comparison of Vivo Bio Tech's Debt-to-Equity

For the Biotechnology subindustry, Vivo Bio Tech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivo Bio Tech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivo Bio Tech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vivo Bio Tech's Debt-to-Equity falls into.

Vivo Bio Tech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vivo Bio Tech's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(193.042	+	430.916)	/	518.732
	=	1.20

Vivo Bio Tech's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Vivo Bio Tech (BOM:511509) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vivo Bio Tech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vivo Bio Tech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivo Bio Tech (BOM:511509) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivo Bio Tech Ltd (BOM:511509) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Number 8-2-672/ 5 and 6, Road Number 1, 3rd Floor, Ilyas Mohammed Khan Estate, Banjara hills, Hyderabad, TG, IND, 500034

Website

http://www.vivobio.com

Vivo Bio Tech Ltd offers drug development and discovery services to pharmaceutical and biotech companies. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. It offers services in the areas of pharmacology, toxicology, pathology, analytical chemistry, lab animal diagnostics, custom model generation, custom breeding, surgical models, and molecular biology.

Vivo Bio Tech (BOM:511509) Headlines

No Headlines